<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Rare Actionable Fusion Driver Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-4</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-4</p>
                <p><strong>Name:</strong> Rare Actionable Fusion Driver Theory</p>
                <p><strong>Type:</strong> specific</p>
                <p><strong>Theory Query:</strong> Build a theory of what drives lung adenocarcinomas that lack known driver alterations in the RTK/RAS/RAF pathway, based on the following results.</p>
                <p><strong>Description:</strong> A small but clinically significant subset (~2-5%) of RTK/RAS/RAF-negative lung adenocarcinomas harbor rare oncogenic gene fusions involving kinases or transcription factors that were historically missed by targeted mutation panels but are detectable by RNA sequencing or comprehensive DNA sequencing. These include known rare fusions (ROS1, RET, NTRK1 fusions in driver-negative contexts) and potentially novel fusions (FOXK2-KRT20, RUNX1-FARS2, FOXN1-BLMH, SCAF11-PDGFRA) that create chimeric proteins with oncogenic properties and may be therapeutically targetable.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Rare Kinase Fusion Driver Principle</h3>
            <p><strong>Statement:</strong> In lung adenocarcinomas lacking mutations in EGFR, KRAS, BRAF, and standard ALK testing, approximately 1-2% harbor ROS1 gene fusions (CD74-ROS1, SLC34A2-ROS1, SDC4-ROS1, CCDC6-ROS1) and ~1% harbor RET gene fusions (KIF5B-RET), which activate downstream RTK signaling (SHP-2, ERK, STAT3, AKT pathways), are mutually exclusive with canonical point driver mutations, and predict sensitivity to kinase inhibitors (crizotinib for ROS1, emerging RET inhibitors).</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinomas profiled by RNA sequencing, break-apart FISH, or comprehensive DNA fusion detection panels; frequencies of ~1-2% for ROS1 and ~0.9-1.7% for RET cited across multiple studies; enriched in never-smokers and younger patients; detectable only by fusion-specific assays not captured by standard mutation panels; primarily adenocarcinoma histology.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Multiple ROS1 fusion partners exist with varying breakpoints and potentially different drug sensitivities</li>
                <li>KIF5B-RET fusion has multiple isoforms depending on breakpoint (exon 15, 16, or 23 of KIF5B to exon 12 of RET)</li>
                <li>Break-apart FISH can miss fusions with intrachromosomal rearrangements or unusual partners</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>CD74-ROS1 and SLC34A2-ROS1 fusions detected at 1.0% (2/202) in never-smoker cohort with high ROS1 mRNA expression and sensitivity to crizotinib demonstrated in prior studies; novel CCDC6-ROS1 fusion detected (1/87 RNA-seq samples) with retained kinase domain and dimerization unit <a href="../results/extraction-result-13.html#e13.9" class="evidence-link">[e13.9]</a> <a href="../results/extraction-result-27.html#e27.10" class="evidence-link">[e27.10]</a> <a href="../results/extraction-result-27.html#e27.11" class="evidence-link">[e27.11]</a> </li>
    <li>ROS1 fusions identified by FISH screening at ~1.2% (5/428 evaluable TMA samples) and ~1.4% (2/138) in Swiss never-smoker cohort; SDC4-ROS1 fusion detected in University of Colorado patient with confirmed partial response to crizotinib (57% tumor shrinkage); ROS1 fusions activate SHP-2, ERK, STAT3 and AKT signaling <a href="../results/extraction-result-93.html#e93.0" class="evidence-link">[e93.0]</a> <a href="../results/extraction-result-93.html#e93.1" class="evidence-link">[e93.1]</a> <a href="../results/extraction-result-11.html#e11.8" class="evidence-link">[e11.8]</a> <a href="../results/extraction-result-18.html#e18.7" class="evidence-link">[e18.7]</a> </li>
    <li>KIF5B-RET fusion (~6% estimated frequency in driver-negative subsets, 3/21 samples analyzed with ~4.3-8% range) detected by whole-genome and transcriptome sequencing showing chromosomal inversion with high fusion transcript expression (~10Ã— higher than controls) and exclusive RET kinase domain exon expression; KIF5B-RET detected in 4/87 RNA-seq subset (mutually exclusive with canonical point drivers, P<0.05) <a href="../results/extraction-result-92.html#e92.0" class="evidence-link">[e92.0]</a> <a href="../results/extraction-result-27.html#e27.9" class="evidence-link">[e27.9]</a> </li>
    <li>RET fusions detected at 1.4% (2/138) in Swiss never-smoker cohort and ~0.9% (TCGA) and ~1-1.7% in various studies; CD74-ROS1 mentioned as most common ROS1 fusion partner <a href="../results/extraction-result-11.html#e11.9" class="evidence-link">[e11.9]</a> <a href="../results/extraction-result-25.html#e25.9" class="evidence-link">[e25.9]</a> <a href="../results/extraction-result-24.html#e24.7" class="evidence-link">[e24.7]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> existing</p>
        <p><strong>Explanation:</strong> ROS1 and RET fusions are established entities in lung cancer with FDA-approved targeted therapies; their role in driver-negative subsets represents clinical characterization rather than novel biology.</p>            <p><strong>What Already Exists:</strong> ROS1 and RET fusions in lung cancer were discovered in 2007 (ROS1) and 2012 (RET); their oncogenic properties and targetability with kinase inhibitors are well-established; clinical testing for these fusions is now standard of care.</p>            <p><strong>What is Novel:</strong> The specific quantification of these fusions in driver-negative subsets (~4.3-8% for RET in triple-negative, enrichment in driver-negative contexts), novel fusion partners (SDC4-ROS1, CCDC6-ROS1), and comprehensive characterization across multiple cohorts represent incremental advances.</p>
        <p><strong>References:</strong> <ul>
    <li>Rikova et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases [ROS1 fusion discovery]</li>
    <li>Kohno et al. (2012) KIF5B-RET fusions in lung adenocarcinoma [RET fusion discovery]</li>
    <li>Shaw et al. (2014) Crizotinib in ROS1-rearranged NSCLC [Clinical trial establishing efficacy]</li>
    <li>Gautschi et al. (2017) Targeting RET in patients with RET-rearranged lung cancers [RET inhibitor trials]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Novel Non-Kinase Fusion Principle</h3>
            <p><strong>Statement:</strong> RNA sequencing of driver-negative lung adenocarcinomas identifies rare gene fusions not involving canonical kinases, including fusions between transcription factors and structural proteins (FOXK2-KRT20), transcription factors and metabolic enzymes (RUNX1-FARS2, FOXN1-BLMH), and promoter-swapping events activating receptor tyrosine kinases (SCAF11-PDGFRA), which are validated by PCR but lack functional characterization and may represent a heterogeneous class of potential drivers with unknown therapeutic relevance.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinomas with RNA sequencing data and computational fusion detection (e.g., DeFuse, other algorithms); novel fusions observed as rare events (singletons or low frequency) in screening cohorts; validation by RT-PCR and Sanger sequencing performed but functional studies generally lacking; enrichment in fusion-positive/driver-negative subset not systematically quantified.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some detected fusions may be transcriptional read-through artifacts or passenger events</li>
                <li>In-frame versus out-of-frame fusions have different likelihood of functional relevance</li>
                <li>Promoter-swapping fusions may cause overexpression rather than creating chimeric proteins</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>FOXK2-KRT20 fusion experimentally validated as novel fusion identified in EAGLE transcriptome data by DeFuse, confirmed by RT-PCR and Ion PGM sequencing <a href="../results/extraction-result-12.html#e12.15" class="evidence-link">[e12.15]</a> </li>
    <li>RUNX1-FARS2 fusion (RUNX1 transcription factor to FARS2 mitochondrial aminoacyl-tRNA synthetase) experimentally validated by RNA-seq discovery and RT-PCR/Ion PGM sequencing; oncogenic role not established <a href="../results/extraction-result-12.html#e12.16" class="evidence-link">[e12.16]</a> </li>
    <li>FOXN1-BLMH fusion (FOXN1 transcription factor to BLMH bleomycin hydrolase) validated by PCR and targeted sequencing as one of 10 validated fusions in EAGLE dataset <a href="../results/extraction-result-12.html#e12.14" class="evidence-link">[e12.14]</a> </li>
    <li>SCAF11-PDGFRA promoter-swap fusion placing PDGFRA under SCAF11 promoter control detected in 1/87 RNA-seq samples in tumor lacking canonical drivers, validated by PCR/Sanger; inferred to cause PDGFRA overexpression and potential oncogenic RTK signaling but no direct functional validation <a href="../results/extraction-result-27.html#e27.14" class="evidence-link">[e27.14]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: green; font-weight: bold;">new</span></p>
        <p><strong>Explanation:</strong> These represent novel molecular entities identified through systematic RNA-seq screening, but without functional validation their biological and clinical significance remains uncertain.</p>            <p><strong>What Already Exists:</strong> Gene fusions as oncogenic drivers in cancer are well-established; computational fusion detection from RNA-seq is a standard approach; non-kinase fusions have been described in various cancers.</p>            <p><strong>What is Novel:</strong> The specific novel fusions (FOXK2-KRT20, RUNX1-FARS2, FOXN1-BLMH, SCAF11-PDGFRA) identified in lung adenocarcinoma are new discoveries, though their functional significance and driver versus passenger status remain unvalidated.</p>
        <p><strong>References:</strong> <ul>
    <li>Campbell et al. (2016) Somatic genomics and clinical features of lung adenocarcinoma [Identification of novel fusions]</li>
    <li>Mitelman et al. (2007) The impact of translocations and gene fusions on cancer causation [General fusion biology]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Driver-negative lung adenocarcinomas screened by RNA sequencing will identify additional ROS1 and RET fusions missed by standard DNA-based testing</li>
                <li>ROS1-fusion-positive driver-negative tumors will respond to crizotinib or other ROS1 inhibitors with objective response rates comparable to ALK-fusion-positive tumors treated with ALK inhibitors</li>
                <li>KIF5B-RET fusion-positive tumors will show elevated RET kinase activity and sensitivity to selective RET inhibitors (selpercatinib, pralsetinib)</li>
                <li>Break-apart FISH will identify ROS1 and RET fusions in driver-negative tumors at frequencies of ~1-2% when systematically applied</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Whether novel non-kinase fusions (FOXK2-KRT20, RUNX1-FARS2, FOXN1-BLMH) are truly oncogenic drivers or passenger events in driver-negative tumors</li>
                <li>Whether promoter-swapping fusions like SCAF11-PDGFRA create therapeutic vulnerabilities to kinase inhibitors (e.g., PDGFR inhibitors)</li>
                <li>Whether systematic RNA sequencing of all driver-negative tumors will reveal a 'long tail' of rare private fusions each occurring at <1% frequency but collectively accounting for a significant fraction</li>
                <li>Whether specific fusion partners or breakpoints predict differential drug sensitivity or resistance mechanisms</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Demonstrating that ROS1 or RET fusion-positive tumors do not show activation of downstream RTK signaling pathways would challenge their role as drivers</li>
                <li>Showing that novel fusions (FOXK2-KRT20, RUNX1-FARS2, etc.) are present at similar frequencies in normal lung tissue would indicate they are not tumor-specific and likely passengers</li>
                <li>Finding that ectopic expression of novel fusion proteins does not transform cells or provide growth advantage would challenge their oncogenic role</li>
                <li>Demonstrating that ROS1 or RET fusion-positive tumors do not respond to targeted kinase inhibitors would challenge their therapeutic relevance</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The true population frequency of novel non-kinase fusions and whether they collectively account for a meaningful fraction of driver-negative tumors <a href="../results/extraction-result-12.html#e12.15" class="evidence-link">[e12.15]</a> <a href="../results/extraction-result-12.html#e12.16" class="evidence-link">[e12.16]</a> <a href="../results/extraction-result-12.html#e12.14" class="evidence-link">[e12.14]</a> </li>
    <li>Whether novel fusions identified through RNA-seq represent real genomic rearrangements or transcriptional artifacts/read-through <a href="../results/extraction-result-27.html#e27.14" class="evidence-link">[e27.14]</a> </li>
    <li>The functional mechanisms by which non-kinase fusions (transcription factor-structural protein, transcription factor-enzyme) might drive oncogenesis <a href="../results/extraction-result-12.html#e12.15" class="evidence-link">[e12.15]</a> <a href="../results/extraction-result-12.html#e12.16" class="evidence-link">[e12.16]</a> </li>
    <li>Whether different ROS1 and RET fusion partners have differential sensitivity to kinase inhibitors <a href="../results/extraction-result-93.html#e93.1" class="evidence-link">[e93.1]</a> <a href="../results/extraction-result-27.html#e27.11" class="evidence-link">[e27.11]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>